XSHG603669
Market cap490mUSD
Jan 09, Last price
5.04CNY
1D
0.81%
1Q
13.67%
Jan 2017
-54.42%
IPO
-26.15%
Name
Lionco Pharmaceutical Group Co Ltd
Chart & Performance
P/E
—
P/S
18.47
EPS
—
Div Yield, %
0.22%
Shrs. gr., 5y
0.30%
Rev. gr., 5y
-34.79%
Revenues
197m
-31.95%
Net income
-151m
CFO
-38m
Dividend
Jul 05, 20220.1 CNY/sh
Earnings
May 16, 2025
Profile
Lionco Pharmaceutical Group Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in China. The company offers nutrition, antimicrobial, antiviral, digestion, cardiovascular, detoxification, anti-tumor, and other products. It also operates research institutes that specialize in the research of chemical drugs, natural medicines, and biological drugs. Lionco Pharmaceutical Group Co., Ltd. was founded in 2003 and is based in Shannan, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 196,831 -31.95% | 289,263 -60.93% | |||||||
Cost of revenue | 263,190 | 374,528 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (66,358) | (85,265) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | 541 | 6,942 | |||||||
Tax Rate | |||||||||
NOPAT | (66,899) | (92,207) | |||||||
Net income | (151,496) | ||||||||
Dividends | (8,083) | (71,761) | |||||||
Dividend yield | 0.20% | 1.74% | |||||||
Proceeds from repurchase of equity | (52,106) | ||||||||
BB yield | 1.31% | ||||||||
| Debt | |||||||||
Debt current | 120,427 | 206,386 | |||||||
Long-term debt | 451,028 | 414,654 | |||||||
Deferred revenue | 2,804 | 4,089 | |||||||
Other long-term liabilities | 1 | ||||||||
Net debt | 127,162 | (344,237) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (37,875) | ||||||||
CAPEX | (23,132) | ||||||||
Cash from investing activities | (51,897) | 131,544 | |||||||
Cash from financing activities | (473,346) | ||||||||
FCF | (32,320) | (52,812) | |||||||
| Balance | |||||||||
Cash | 734,009 | 965,277 | |||||||
Long term investments | (289,715) | ||||||||
Excess cash | 434,452 | 950,814 | |||||||
Stockholders' equity | 639,408 | 903,430 | |||||||
Invested Capital | 1,065,007 | 851,719 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 721,407 | 718,452 | |||||||
Price | 5.53 -3.66% | 5.74 -42.54% | |||||||
Market cap | 3,989,382 -3.26% | 4,123,914 -46.69% | |||||||
EV | 4,116,544 | 3,779,677 | |||||||
EBITDA | (16,910) | (39,941) | |||||||
EV/EBITDA | |||||||||
Interest | 3,710 | 5,832 | |||||||
Interest/NOPBT | |||||||||